会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 15. 发明公开
    • 에리시펠로트릭스루시오페이취에(Erysipelothrixrhusiopathiae)-헤모필루스파라수이스(Haemophilus Parasuis)백신 및 이들을 이용하는 방법
    • ER IX IX IX IX IX US IS IS IS AME AME AME AME AME AME AME AME AME AME AME AME AME AME
    • KR1020060105763A
    • 2006-10-11
    • KR1020067010570
    • 2004-10-29
    • 베링거잉겔하임베트메디카인코퍼레이티드
    • 스와트,존란달바우겐,에릭마틴프레킹,카렌이.루프,마이클비.하예스,필립웨인필립스,레이드씨.
    • A61K39/085
    • A61K39/102A61K39/0241A61K2039/54A61K2039/552A61K2039/55566
    • The present invention provides a composition and an improved single dose vaccine against E. rhusiopathiae and an improved single dose vaccine against E.rhusiopathiae andH. parasuis which provides one or more of the following: 1) confers effective immunity against E. rhusiopathiae and/or H. parasuis; 2) decreases the risk of developing clinical signs of E. rhusiopathiae and/or H.parasuis infection; 3) induces an immune response against E. rhusiopathiae and/or H. parasuis; and 4) has a DOI against E. rhusiopathiae and/or H. parasuis of at least four months. The composition or E. rhusiopathiae vaccine as well as the combined E. rhusiopathiae-H. parasuis composition or vaccine each includes a bacterial component of inactivated E. rhusiopathiae bacteria and a suitable adjuvant. The combined E. rhusiopathiae-H. parasuis composition or vaccine further includes an amount of H. parasuis antigen. The vaccines can be administered to animals in any conventional manner. The amount of the dose for intramuscular administration is preferably less than 5 ml. The amount of E.rhusiopathiae and/or H. parasuis antigen in each dose should be enough to induce an immune response in the animal receiving the vaccine or composition and will preferably confer effective immunity against and decrease the risk of developing clinical signs resulting from E. rhusiopathiae and/or H. parasuis infection for a suitable duration of immunity.
    • 本发明提供一种组合物和改进的针对埃氏杆菌病的单剂量疫苗,以及针对E.rhusiopathiae和H的改进的单剂量疫苗。 提供以下一个或多个的副产物:1)赋予对脑炎杆菌和/或副猪嗜血杆菌的有效免疫; 2)降低发生脑脊液感染和/或幽门螺杆菌感染的临床体征的风险; 3)诱导针对埃氏杆菌和/或副猪嗜血杆菌的免疫应答; 和4)具有至少四个月的针对E.hathiopathiae和/或副猪嗜血杆菌的DOI。 组合物或E.杆菌病疫苗以及组合的脑炎病毒H。 副产物组合物或疫苗各自包括灭活的肠球菌属细菌的细菌组分和合适的佐剂。 合并的脑炎病毒H。 副产物组成或疫苗还包括一定量的副猪嗜血杆菌抗原。 疫苗可以以任何常规方式施用于动物。 肌内给药的剂量优选小于5ml。 每种剂量中的胡须虫病毒和/或副猪嗜血杆菌抗原的量应足以在接种疫苗或组合物的动物中诱导免疫应答,并且优选赋予有效的免疫力并降低由E引起的临床体征的风险 rhusiopathiae和/或副猪嗜血杆菌感染,具有合适的免疫持续时间。